News Releases | Subscribe

April 17, 2019

Myriad Genetics Named to Forbes 2019 List of America's Best Midsize Employers and the Women Tech Council’s 2019 Shatter List

Creating a Culture of Diversity, Inclusion and Opportunity Is a Top Company Priority SALT LAKE CITY, April 17, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced today announced that the company was named to Forbes 2019 list

Read More

April 9, 2019

Myriad Genetics Submits First Module of the Premarket Approval Application to FDA for the myChoice® HRD CDx Test

myChoice HRD Is Intended to Identify Patients with Ovarian, Fallopian or Primary Peritoneal Cancer Who May Benefit from Treatment with Zejula SALT LAKE CITY, April 09, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in personalized medicine, today announced that it has

Read More

April 4, 2019

Myriad, AstraZeneca and Merck Expand Companion Diagnostic Partnership

BRACAnalysis CDx® Test Will Be Used to Identify Germline BRCA Mutations in Men with Metastatic Castrate-Resistant Prostate Cancer SALT LAKE CITY, April 04, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics , Inc. (NASDAQ: MYGN), a leader in personalized medicine, today announced that it has expanded its

Read More

February 5, 2019

Myriad Genetics Reports Fiscal Second-Quarter 2019 Financial Results

Total Second-Quarter Revenues of $216.8 Million, Up 15 Percent Second-Quarter Diluted EPS of $0.03 and Adjusted EPS of $0.38, Up 6 Percent SALT LAKE CITY, Feb. 05, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in molecular diagnostics and

Read More

November 19, 2018

Myriad Announces $50 Million Accelerated Share Repurchase Program

SALT LAKE CITY, Nov. 19, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced that the company has entered into an accelerated share repurchase (“ASR”) agreement with Bank of America, N.A.

Read More

November 6, 2018

Myriad Genetics Reports Fiscal First-Quarter 2019 Financial Results

Total First-Quarter Revenues of $202.3 Million, Up 13 Percent First-Quarter Diluted EPS of ($0.01) and Adjusted EPS of $0.43, Up 48 Percent Revised Full-Year Revenue Guidance to $855 to $865 Million; Maintained Diluted EPS Guidance of $0.40 to $0.45 and Adjusted EPS Guidance of $1.70 to $1.75 SALT

Read More

April 17, 2019

Myriad Genetics Named to Forbes 2019 List of America's Best Midsize Employers and the Women Tech Council’s 2019 Shatter List

Creating a Culture of Diversity, Inclusion and Opportunity Is a Top Company Priority SALT LAKE CITY, April 17, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced today announced that the company was named to Forbes 2019 list

Read More

February 13, 2019

Myriad Genetics to Present at Multiple Upcoming Healthcare Conferences

SALT LAKE CITY, Feb. 13, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and personalized medicine, announced that it will be presenting at multiple upcoming healthcare conferences. R. Bryan Riggsbee, chief financial officer at Myriad Genetics will

Read More

January 28, 2019

Myriad to Announce Fiscal Second-Quarter 2019 Financial Results on February 5, 2019

SALT LAKE CITY, Jan. 28, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and personalized medicine, today announced that it will hold its fiscal second-quarter 2019 sales and earnings conference call with investors and analysts at 4:30 p.m.

Read More

April 9, 2019

Myriad Genetics Submits First Module of the Premarket Approval Application to FDA for the myChoice® HRD CDx Test

myChoice HRD Is Intended to Identify Patients with Ovarian, Fallopian or Primary Peritoneal Cancer Who May Benefit from Treatment with Zejula SALT LAKE CITY, April 09, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in personalized medicine, today announced that it has

Read More

April 4, 2019

Myriad, AstraZeneca and Merck Expand Companion Diagnostic Partnership

BRACAnalysis CDx® Test Will Be Used to Identify Germline BRCA Mutations in Men with Metastatic Castrate-Resistant Prostate Cancer SALT LAKE CITY, April 04, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics , Inc. (NASDAQ: MYGN), a leader in personalized medicine, today announced that it has expanded its

Read More

April 2, 2019

Myriad Women’s Health to Highlight New Studies Demonstrating the Superior Clinical Performance of the Foresight® and Prequel™ Prenatal Tests

SALT LAKE CITY, April 02, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced that its Myriad Women’s Health business unit will present results from two important studies at the 2019 American College of Medical Genetics and

Read More

April 9, 2019

Myriad Genetics Submits First Module of the Premarket Approval Application to FDA for the myChoice® HRD CDx Test

myChoice HRD Is Intended to Identify Patients with Ovarian, Fallopian or Primary Peritoneal Cancer Who May Benefit from Treatment with Zejula SALT LAKE CITY, April 09, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in personalized medicine, today announced that it has

Read More

April 4, 2019

Myriad, AstraZeneca and Merck Expand Companion Diagnostic Partnership

BRACAnalysis CDx® Test Will Be Used to Identify Germline BRCA Mutations in Men with Metastatic Castrate-Resistant Prostate Cancer SALT LAKE CITY, April 04, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics , Inc. (NASDAQ: MYGN), a leader in personalized medicine, today announced that it has expanded its

Read More

April 2, 2019

Myriad Women’s Health to Highlight New Studies Demonstrating the Superior Clinical Performance of the Foresight® and Prequel™ Prenatal Tests

SALT LAKE CITY, April 02, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced that its Myriad Women’s Health business unit will present results from two important studies at the 2019 American College of Medical Genetics and

Read More

Myriad Corporate Presentation
Fact Sheet
Company Milestones